As of 2022, trastuzumab-deruxtecan (T-DXD) and a combination of capecitabine, trastuzumab and tucatinib have been added to the treatment landscape of patients with HER2 + advanced breast cancer (ABC) [5]. Here, ERBB2 is linked to breast cancer.